On or around 09/04/2020 (Date of last review)
Filing Date: September 03, 2020
According to the Complaint, Fennec Pharmaceuticals Inc. is a biopharmaceutical company that purportedly focuses on the development of PEDMARK, a sodium thiosulfate anhydrous injection, for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Company & Securities Information
Defendant: Fennec Pharmaceuticals Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: FENC
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jim Chapman, et al. v. Fennec Pharmaceuticals Inc., et al.
COURT: M.D. North Carolina
DOCKET #: 20-CV-00812
DATE FILED: 09/03/2020
CLASS PERIOD START: 02/11/2020
CLASS PERIOD END: 08/10/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Glancy Prongay & Murray LLP
The Law Offices of Frank R. Cruz
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of the Federal Securities Laws
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available